{
  "nctId": "NCT01880957",
  "briefTitle": "PET and MRI Brain Imaging of Bipolar Disorder",
  "officialTitle": "Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging",
  "protocolDocument": {
    "nctId": "NCT01880957",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2019-12-13",
    "uploadDate": "2022-03-21T21:14",
    "size": 982168,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT01880957/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NON_RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 76,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2011-11-08",
    "completionDate": "2017-06-23",
    "primaryCompletionDate": "2017-06-23",
    "firstSubmitDate": "2013-06-17",
    "firstPostDate": "2013-06-19"
  },
  "eligibilityCriteria": {
    "criteria": "PATIENTS\n\nBIPOLAR\n\nInclusion Criteria:\n\n* Bipolar patients suffering from a major depressive episode currently or recently (in the month prior to scanning). Patients on psychiatric medication will have failed their current regimen for the treatment of their depression: they will meet criteria for depression, be seeking treatment for it, and have been on an adequate dose of antidepressant or mood stabilizer (as defined by the Antidepressant Treatment Form-see Oquendo et al., 2003) for 4 weeks or more.\n* Of sufficient severity to score at least 15 on the first 17 items of the Hamilton Depression Rating Scale or a score of 10 to 14 on the first 17 items of the Hamilton Depression Scale in conjunction with a score of at least 29 on the Beck Depression Inventory.\n* Age range 18-65 years.\n* Off all psychotropic and other types of drugs likely to interact with serotonin transporters and 5-HT1A receptors for at least 21 days. Allowed short-acting benzodiazepines for distressing anxiety or insomnia (up to 24 hours prior to each PET scan). Patients will be off neuroleptics for 3 weeks and off fluoxetine for 6 weeks prior to study. Off serotonin depleting drugs such as reserpine for 3 months. Patient will also be off anti-coagulant/anti-platelet treatment such as coumadin, with the exception of aspirin for 10 days.\n* Willing to travel for PET scanning\n\nExclusion Criteria:\n\n* Other major psychiatric disorders such as schizophrenia, schizoaffective illness; current drug or alcohol abuse (within past 2 months), or drug or alcohol dependence \\<6mos ago; anorexia nervosa or bulimia nervosa in the past year; IV drug use or ecstasy use more than two times.\n* A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations).\n* Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss and the lab parameters platelet count \\< 80,000.\n* Lacks capacity to consent.\n* Actively suicidal-begins expressing a plan for suicide during the washout phase or develop suicidal ideation that warrants admission or requires medication or treatment intervention.\n* Electroconvulsive therapy (ECT) within the past 6 months.\n* Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.\n* Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel\n* Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.\n* A neurological disease or loss of consciousness for more than a few minutes\n* Medicinal Patch (participants will be asked to remove before MRI)\n* Patients who are responding satisfactorily to psychiatric medications, because they will not be washed-out for purposes of this study\n* A documented history of a lack of response to a trial of adequate dose and duration of both lithium and lamotrigine defined as minimal clinical response to lamotrigine 200 mgs for at least 4 weeks or lithium serum levels of at least 0.8 (or dose \\>= 900 mgs) for at least 4 weeks.\n* Patient is unlikely to be able to tolerate medication washout\n* Claustrophobia\n* Blood donation within 8 weeks of the start of the study.\n* History of bleeding disorder or are currently taking anticoagulants.\n\nUNIPOLAR\n\nInclusion:\n\n* Unipolar patients suffering from a major depressive episode currently or recently (in the month prior to scanning). Patients on psychiatric medication will have failed their current regimen for the treatment of their depression: they will meet criteria for depression, be seeking treatment for it, and have been on an adequate dose of antidepressant or mood stabilizer (as defined by the Antidepressant Treatment Form-see Oquendo et al., 2003) for 4 weeks or more.\n* Of sufficient severity to score at least 15 on the first 17 items of the Hamilton Depression Rating Scale or a score of 10 to 14 on the first 17 items of the Hamilton Depression Scale in conjunction with a score of at least 29 on the Beck Depression Inventory.\n* Age range 18-65 years.\n* Off all psychotropic and other types of drugs likely to interact with serotonin transporters and 5-HT1A receptors for at least 21 days. Allowed short-acting benzodiazepines for distressing anxiety or insomnia (up to 24 hours prior to each PET scan). Patients will be off neuroleptics for 3 weeks and off fluoxetine for 6 weeks prior to study. Off serotonin depleting drugs such as reserpine for 3 months. Patient will also be off anti-coagulant/anti-platelet treatment such as coumadin, with the exception of aspirin for 10 days.\n* Willing to travel for PET scanning\n\nExclusion:\n\n* Other major psychiatric disorders such as schizophrenia, schizoaffective illness; current drug or alcohol abuse (within past 2 months), or drug or alcohol dependence \\<6mos ago; anorexia nervosa or bulimia nervosa in the past year; IV drug use or ecstasy use more than two times.\n* A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations).\n* Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss and the lab parameters platelet count \\< 80,000.\n* Lacks capacity to consent.\n* Actively suicidal-begins expressing a plan for suicide during the washout phase or develop suicidal ideation that warrants admission or requires medication or treatment intervention.\n* Electroconvulsive therapy (ECT) within the past 6 months.\n* Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.\n* Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel\n* Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.\n* A neurological disease or loss of consciousness for more than a few minutes\n* Medicinal Patch (participants will be asked to remove before MRI)\n* Patients who are responding satisfactorily to psychiatric medications, because they will not be washed-out for purposes of this study\n* A documented history of a lack of response to a trial of adequate dose and duration of both lithium and lamotrigine defined as minimal clinical response to lamotrigine 200 mgs for at least 4 weeks or lithium serum levels of at least 0.8 (or dose \\>= 900 mgs) for at least 4 weeks.\n* Patient is unlikely to be able to tolerate medication washout\n* Claustrophobia\n* Blood donation within 8 weeks of the start of the study.\n* History of bleeding disorder or are currently taking anticoagulants.\n* Past unsuccessful treatment of Lithium of adequate dose and duration.\n\nHEALTHY CONTROLS\n\nInclusion:\n\n* No lifetime history of Axis I disorders\n* Age range 18-65 years.\n* Willing to travel for PET scanning.\n\nExclusion:\n\n* Past or present alcohol/substance abuse or dependence; IV drug use or ecstasy use more than two times.\n* A first-degree relative with history of major depression, schizophrenia, schizoaffective disorder, or suicide attempt; two or more first degree relatives with a history of substance dependence.\n* Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss, and the following lab parameters: platelet count \\< 80,000\n* Lacks capacity to consent\n* Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months\n* Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel\n* Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.\n* A neurological disease or loss of consciousness for more than a few minutes\n* Medicinal Patch (participants will be asked to remove before MRI)\n* Subjects on drugs or medication that affect the serotonin system\n* Claustrophobia\n* Blood donation within 8 weeks of the start of the study.\n* History of bleeding disorder or are currently taking anticoagulants.",
    "healthyVolunteers": true,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Post-Lithium Treatment Hamilton Depression Rating Scale (HDRS)",
        "description": "Patients will have a Hamilton Depression Rating Scale-24 (HDRS) score obtained at baseline. Minimum score 0, maximum possible score 75; the higher the score on the scale, the more severe the degree of depression. Participants must have an HDRS score of at least 15 to be eligible. After eight weeks of medication treatment, the HDRS score will be reevaluated with the HDRS-24 (and rescanned with PET and MRI). Participants who have a 50% or greater decrease in their HDRS-24 score will be considered responders (to Lithium treatment).",
        "timeFrame": "8 weeks"
      },
      {
        "measure": "Prediction of Treatment Response",
        "description": "Outcome measures were generated following LASSO linear regression analysis using pretreament HDRS-24 AND..\n\n1. pre-treatment 5-HTT OR\n2. pretreatment 5-HT1A OR\n3. the combination of both 5-HTT and 5-HT1A binding potential\n\n   * to predict post-treatment response defined by a dichotomous remission status variable (remitter vs. non-remitter, where remitter is defined a priori by HDRS-24 \\<10 post-treatment and a reduction of greater than or equal to 50% in HDRS-24 pre-to-post treatment). Outcome measure is reported as percent accuracy, sensitivity, or specificity in predicting remitter status outcomes.",
        "timeFrame": "8 Weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Group Differences in 5-HTT Binding Potential",
        "description": "Differences in mean of 5-HTT binding potential between patients with depression pre-treatment, post-treatment, compared to healthy volunteers. Broadly, binding potential is defined as the ratio of the tracer concentration in tissue to the free plasma concentration. It is a measure of the density of \"available\" targets (e.g. 5-HTT) \\& the affinity of the ligand (tracer) to that target.",
        "timeFrame": "8 Weeks"
      },
      {
        "measure": "Group Differences in 5-HT1A Binding Potential",
        "description": "Differences in mean of 5-HT1A binding potential between patients with depression pre-treatment, post-treatment, compared to healthy volunteers. Broadly, binding potential is defined as the ratio of the tracer concentration in tissue to the free plasma concentration. It is a measure of the density of \"available\" targets (e.g. 5-HT1A) \\& the affinity of the ligand (tracer) to that target.",
        "timeFrame": "8 Weeks"
      },
      {
        "measure": "Relationship Between Change in 5-HTT or 5-HT1A Binding Potential Pre- to Post Treatment and Lithium Treatment Response",
        "description": "Linear regression \\& correlation to assess the relationship between between change in binding potential pre- to post treatment vs. treatment response",
        "timeFrame": "8 weeks"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 3,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 39,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:29:19.162Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}